News
In this category you will find the latest insights from evitria as well as current press releases.
Articles about News (12)
-
AAX Biotech and evitria to expand access to Opti-mAb® technology in early antibody development
STOCKHOLM / 23 April 2026 – Biotech company AAX Biotech, a leading innovator in technologies for antibody-based therapies, today announced a partnership with evitria AG, an expert provider of antibody engineering and expression services, to enable the use of its Opti-mAb® technology in early antibody development workflows. AAX Biotech develops proprietary technologies, including Opti-mAb®, supporting […]
-
Bengt Thorsson and Johan Rockberg to join Atlas Antibodies’ Board of Directors
We are pleased to announce the election of Bengt Thorsson and Johan Rockberg to Atlas Antibodies’ Board of Directors, following the AGM on May 23, 2025. Åsa Riisberg has been re-elected as Chair of the Board and Catarina Flyborg, Gavin Wood, Christian Eberle and Louise Kores have been re-elected as board members. We thank Mathias […]
-
Press release: evitria Celebrates 15 Years with Exclusive Giveaway for Industry Experts
Tickets for Festival of Biologics, Networking Dinner, and Exclusive Tour of evitria AG in Zürich Up for Grabs Zurich, Switzerland – March 2025 – evitria, a leading provider of antibody development services, is celebrating its 15th anniversary with an exciting giveaway that offers an exclusive opportunity to attend the Festival of Biologics in Basel, Switzerland. […]
-
Engineering bispecific antibodies
Recorded Presentation: From mAb to bAb Developing drugs requires navigating complex technical, practical, and strategic challenges quickly. Optimizing a drug’s activity and effectiveness and subsequently considering the IP landscape are crucially important balancing acts. Here, we demonstrate how evitria’s extensive expertise in antibody production can help you engineer, reformat, and produce your therapeutic, using a […]
-
evitria and Lonza Sign License Agreement to Provide Fast Access to bYlok® Bispecific Antibodies for Discovery-Stage Transient Expression Research
Zurich-based evitria AG has entered a non-exclusive license agreement with Lonza for its bYlok® technology, enabling simple and reliable development of IgG-like bispecific antibodies.
-
Bespoke solutions for lead selection and optimization in cancer antibody research
In this Webinar, Richard Park from evitria, will present Case Studies on Flexibility: Bespoke Solutions for Lead Selection & Optimization in Cancer Antibody Research – get your video now!
-
The Shortcut to Reliable Diagnostic, Control, and Assay Antibodies
In this webinar, we present a single integrated workflow for antibody sequencing and recombinant expression of mAbs. We will present a case study of a successful mAb-to-rAb conversion, describe the methodology in detail, and explain how it can be used to efficiently convert a catalog of mAb or pAb reagents into recombinant antibodies.
-
Dr. Stefan Schmidt new CEO of evitria
As of May 2023, Dr. Stefan Schmidt will take over the position of CEO at evitria. Read more about Dr. Schmidt and his vision for the company in this article.
-
Schweizer Expertise weltweit gefragt – evitria setzt Wachstumskurs fort
Das Team von evitria blickt auf Meilensteine und Errungenschaften zurück und setzt das Wachstum des Unternehmens auch 2023 fort.
-
20,000 antibodies purified – major milestone at evitria
With more than 20,000 abs and proteins purified, evitria has reached a huge milestone. Read more about its significance and our plans for the future.
-
Press release: Genovis AB enters service agreement with evitria AG for fast LC-MS analysis of recombinant antibodies
Genovis AB and evitria AG signed a service agreement to offer evitria’s customers fast LC-MS characterization of recombinant antibodies using Genovis proprietary enzyme technologies. evitria AG is a world leading service provider for recombinant antibody expression in CHO cells, with headquarters in Zürich, Switzerland.
-
Press release: evitria AG announces license of mAbsolve STR technology
evitria AG, a research, development, and manufacturing organization focused on transient recombinant antibody and protein production, announces the closing of a license agreement with mAbsolve Ltd for mAbsolve’s proprietary STR technology.